Flux Power Holdings Inc vs Viatris Inc — how do they compare? Flux Power Holdings Inc trades at $0.7 (market cap $15.37M), while Viatris Inc trades at $17.29 (market cap $19.44B). The key difference: Viatris Inc is far larger — about 1264.8× Flux Power Holdings Inc's market cap, and Viatris Inc pays a 2.88% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | VTRS | |
|---|---|---|
Market Cap | $15.37M | $19.44B |
Sector | Utilities | Health |
52-Week High | $6.66 | $17.39 |
52-Week Low | $0.71 | $8.74 |
Enterprise Value | $21.53M | $31.65B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.701, down 2.18% today, with a bearish technical signal from moving averages. The company reported a net loss of $6.67M in 2025 with revenue of $66.43M, though the price-to-sales ratio remains low at 0.27. Recent news highlights the launch of SkyEMS 3.0 AI software and new executive hires aimed at growth. Analysts are unanimously bullish with 6 buy ratings, contrasting with negative profitability metrics like a -52.27% ROE.
The outlook hinges on execution of growth initiatives amid persistent losses. Opportunities include market expansion in clean energy and software, while risks involve cash flow volatility and competitive pressures. Investors should weigh analyst optimism against fundamental challenges in the evolving energy storage sector.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Trailing returns across standard periods
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →